The Bone Marrow Transplant Program at Miami Children’s Hospital (MCH) has once again received internationally-recognized accreditation by the Foundation for the Accreditation of Cellular Therapies (FACT) at the University of Nebraska Medical Center. By demonstrating compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration, Miami Children’s Hospital has earned FACT Accreditation for pediatric allogeneic and autologous hematopoietic progenitor cell transplantation; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation.

“We are delighted that the Cancer Center and its Bone Marrow Transplant Program have, once again, received FACT accreditation. This recognition speaks to the dedication of the entire team and assures that patients and families receive the best care possible,” said Dr. Kamar Godder, Director of the Bone Marrow Transplant Program at MCH.

FACT is an internationally-recognized accrediting body for hospitals and medical institutions offering stem cell transplant, and indicates the accredited institution has met the most rigorous standards in every aspect of stem cell therapy. This covers the entire spectrum of stem cell therapy, from clinical care to donor management, cell collection, processing, storage, transportation, administration, and cell release.

MCH’s Cancer Center and Bone Marrow Transplant Program are both the largest providers of cancer and blood disorder services in the region. The center participates in research protocols, offering state-of-the-art care for children with for all forms of cancer and blood disorders.